January 7, 2019
Sanofi to pay Regeneron $462 million as companies restructure immuno-oncology agreement for more independence in each research
Regeneron Pharmaceuticals and Sanofi restructure immuno-oncology agreement from 2015, where Regeneron retains full rights to all its other investigational immunooncology programsto, while Sanofi is able to independently chase own immuno-oncology programs.